SecBot SecBot
PRESS-RELEASE ·Filed Mar 3, 2026

VXRT

Vaxart, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Traders should monitor the March 12 earnings call for potential updates on cash runway, clinical progress, or funding developments, which could impact the stock given Vaxart's clinical-stage status and history of dilution risk.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.7600
T+0 close · Mar 3, 2026 · via day close
Latest settled
−13.16%
T+60 · $0.6600
Vs SPY
−23.25%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 4 $0.7600entry
  2. T+1 · 9mo ago −5.26%α −4.69% · $0.7200
  3. T+5 · 8mo ago +1.32%α +2.65% · $0.7700
  4. T+20 · 8mo ago −17.11%α −12.69% · $0.6300
  5. T+60 · 6mo ago −13.16%α −23.25% · $0.6600

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vaxart, Inc. announced upcoming webcast events to discuss its full-year 2025 financial results and provide a stockholder update. The earnings call is scheduled for March 12, 2026, after market close, followed by a stockholder fireside chat on March 13, 2026. No financial results or material updates were released in this announcement.

Key Facts

  • Vaxart will report full-year 2025 financial results on March 12, 2026, after market close.
  • A conference call and webcast will be held the same day at 4:30 p.m. ET.
  • A stockholder fireside chat is scheduled for March 13, 2026, at 4:30 p.m. ET.
  • No financial data or operational updates were disclosed in this press release.
  • Replays of both events will be available on the company's website.

Financial Impact

No financial impact from this announcement; actual results to be disclosed on March 12.

Risk Factors

  • High volatility expected around earnings announcement due to lack of transparency ahead of the call.
  • Potential for dilutive financing or extended cash runway concerns given Vaxart's pre-revenue biotech profile.

Market Snapshot

Exchange
OTC

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3248893

Track record

23 reports on VXRT

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +37.66% at T+60 after the May 1, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $0.3700 Now $0.3600 +2.70% settles Feb 4
  2. Oct 19, 202628d ago 8-K Neutral 3/10 Entry $0.4900 Now $0.3600 −26.53% settles Jan 15
  3. Jul 28, 202615w ago 8-K Neutral 2/10 Entry $0.4800 to $0.4900 Now $0.3600 −25.00% ▲ +2.08% −2.53% vs SPY
  4. Jul 7, 202618w ago 8-K Neutral 4/10 Entry $0.5500 to $0.4500 Now $0.3600 −34.55% ▼ −18.18% −21.27% vs SPY
  5. Jul 6, 202619w ago DEFA14A Neutral 5/10 Entry $0.6200 to $0.4540 Now $0.3600 −41.94% ▼ −26.77% −28.93% vs SPY
  6. Jul 2, 202619w ago DEFA14A Bullish 5/10 Entry $0.6400 to $0.4500 Now $0.3600 −43.75% ▼ −29.69% −33.51% vs SPY
  7. Jul 2, 202619w ago 8-K Neutral 4/10 Entry $0.6400 to $0.4520 Now $0.3600 −43.75% ▼ −29.38% −32.80% vs SPY
  8. Jun 26, 202620w ago DEFA14A Neutral 4/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
  9. Jun 26, 202620w ago DEFA14A Neutral 3/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
  10. Jun 26, 202620w ago 8-K Mixed 5/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 3, 2026